Kymera Therapeutics (NSDQ:KYMR), as a growing number of biotech companies, is intending to expand the druggable universe.
To that end, the company announced positive data related to targeted protein degradation (TPD). This modality enables oral small-molecule drugs to coax the body into clearing disease-causing proteins.
Kymera’s lead drug candidate, KT-474, targets a key protein known as IRAK4 involved in IL-1R/toll-like receptor–driven diseases such as hidradenitis suppurativa, atopic dermatitis and rheumatoid arthritis.
Recent Phase 1 trial data in healthy volunteers found that the drug promoted levels of IRAK4 protein degradation averaging at least 95%. Furthermore, a single dose led to degradation over six days.
The company also concluded that the drug impacted key biological pathways previously considered undruggable.
Kymera concluded that the drug appears to have the potential for a broad anti-inflammatory effect based on its reducti…